Extended dispensing a ‘win for patients’ Hundreds of medications will become eligible for 60-day supply from September in a move likely to save the healthcare system billions.
RACGP joins fight against asthma med change The college has written to the PBAC Chair about potential grave consequences for families due to new restrictions on fluticasone propionate 50 mcg.
Controversial pharmacy income deal under assessment An agreement that guarantees pharmacies’ income for prescriptions is being reviewed for its ‘fitness for purpose’.
‘A positive step’: oral antivirals confirmed for Doctor’s Bag After extensive RACGP lobbying, GPs now have enhanced access to COVID-19 oral antiviral treatments for urgent use among at-risk patients.
Changes made to recent opioid reforms Annual secondary review requirements have been relaxed, easing access concerns for palliative care patients.
People experiencing psoriasis and asthma receive PBS relief Patients with urea cycle disorder will also benefit from the new round of listings.
Cystic fibrosis drug listed on PBS While the announcement was welcomed, some have questioned the seven month delay between approval and listing.
Cancer and inflammatory disease medicines receive $56 million boost Four new medicines will be listed through the Pharmaceutical Benefits Scheme, helping patients fight aggressive cancers and inflammatory conditions.
Behind the scenes at the PBAC Outgoing RACGP representative Rashmi Sharma pulls back the curtain after 10 years on the Pharmaceutical Benefits Advisory Committee.
Changes to restrictions on medicines for COPD and asthma Dr Kerry Hancock, Chair of the RACGP’s Respiratory Medicine Specific Interests network, examines the reasons behind recent changes to the PBS and what they mean for GPs and patients.